Alkermes (ALKS, Financial) experienced a significant stock price increase, jumping 5.01%. The stock is currently valued at $28.74 per share with a trading volume of 792,642 shares, a turnover rate of 0.48%, and a price fluctuation of 5.26%.
Recent financial reports reveal that Alkermes generated $399 million in revenue with a net profit of $94.66 million. Earnings per share stood at $0.54 with a gross profit of $336 million and a price-to-earnings ratio of 16.79.
Among the 14 institutions rating the stock, 57% recommend buying, 36% suggest holding, and 7% advise selling. The pharmaceutical industry, where Alkermes is positioned, showed an overall increase of 1.30%.
Other notable stocks in the sector include Cyclo Therapeutics Inc, Alpha Teknova, Inc., and Akanda Corp., which showed significant price movements and activity. Cyclo Therapeutics Inc exhibited a price fluctuation of 49.00%, while Akanda Corp. displayed a turnover rate of 108.84%.
Alkermes operates as a fully integrated biotechnology company focusing on the development and commercialization of pharmaceutical products to address unmet medical needs. The company strategically uses its proprietary technology and resources to advance its product offerings, sourcing active drug ingredients from third parties.
